| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Joshua P Sutherland, Ang Zhou, Elina Hyppöne. Muscle Traits, Sarcopenia, and Sarcopenic Obesity: A Vitamin D Mendelian Randomization Study. Nutrients. vol 15. issue 12. 2023-06-28. PMID:37375607. |
for probable sarcopenia risk, there was suggestive evidence for lower odds by higher 25(oh)d (or 0.96 (95% ci 0.92, 1.00)); however, this did not reflect an association with sarcopenic obesity (or 0.97 (95% ci 0.93, 1.02)), but was seen in probable sarcopenia cases who were not obese (or 0.92 (95% ci 0.86, 0.98)). |
2023-06-28 |
2023-08-14 |
mouse |
| Motoki Furutani, Mutsumi Suganuma, Shintaro Akiyama, Risa Mitsumori, Marie Takemura, Yasumoto Matsui, Shosuke Satake, Yukiko Nakano, Shumpei Niida, Kouichi Ozaki, Tohru Hosoyama, Daichi Shigemiz. RNA-sequencing analysis identification of potential biomarkers for diagnosis of sarcopenia. The journals of gerontology. Series A, Biological sciences and medical sciences. 2023-06-22. PMID:37347997. |
we used clinical data which were not included diagnosis criteria of sarcopenia, and stride length showed significance by logistic regression analysis (bonferroni corrected p = .012, odds ratio = 0.06, 95% confidence interval [ci]: 0.05 to 0.40). |
2023-06-22 |
2023-08-14 |
Not clear |
| Sawan Ali, Graziamaria Corbi, Alessandro Medoro, Mariano Intrieri, Giovanni Scapagnini, Sergio Davinell. Relationship between monounsaturated fatty acids and sarcopenia: a systematic review and meta-analysis of observational studies. Aging clinical and experimental research. 2023-06-20. PMID:37340168. |
the results revealed that mufa intake is inversely associated with sarcopenia (standardized mean difference = - 0.28, 95% ci - 0.46 to - 0.11; p < 0.01). |
2023-06-20 |
2023-08-14 |
human |
| Dongwoo Kim, Yu Jin Lee, Eui Seop Song, Ahreum Kim, Cho Hee Bang, Jae Hyun Jun. The High Prevalence of Sarcopenia in Rheumatoid Arthritis in the Korean Population: A Nationwide Cross-Sectional Study. Healthcare (Basel, Switzerland). vol 11. issue 10. 2023-05-27. PMID:37239687. |
after adjusting for potential confounding variables, the prevalence of sarcopenia was higher in men with ra than in men without ra (or, 3.11; 95% ci, 1.29-7.46), but this difference was not observed in women. |
2023-05-27 |
2023-08-14 |
human |
| Dongwoo Kim, Yu Jin Lee, Eui Seop Song, Ahreum Kim, Cho Hee Bang, Jae Hyun Jun. The High Prevalence of Sarcopenia in Rheumatoid Arthritis in the Korean Population: A Nationwide Cross-Sectional Study. Healthcare (Basel, Switzerland). vol 11. issue 10. 2023-05-27. PMID:37239687. |
in subgroup analysis which was stratified by age (age under 40, age between 40 and 59, age over 60), the or for sarcopenia was higher in men with age over 60 years (or, 4.12; 95% ci, 1.48-11.44) and women with age between 40 and 59 (or, 2.29; 95% ci, 1.05-5.00). |
2023-05-27 |
2023-08-14 |
human |
| Takushi Manabe, Chikara Ogawa, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Mitsushige Shibatoge, Asahiro Morishita, Masatoshi Kudo, Tsutomu Masak. Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease. Diagnostics (Basel, Switzerland). vol 13. issue 7. 2023-04-13. PMID:37046463. |
all diagnostic methods showed that patients with sarcopenia had shorter survival, with o-pmi having the highest hazard ratio (hr) (hr, 6.12; 95% confidence interval [ci], 2.6-14.41; |
2023-04-13 |
2023-08-14 |
Not clear |
| Xinrong Zuo, Xuehong Li, Kuo Tang, Rui Zhao, Minming Wu, Yang Wang, Tao L. Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis. Journal of cachexia, sarcopenia and muscle. 2023-04-01. PMID:37002802. |
the prevalence of sarcopenia ranged from 10.1% to 68.9% in patients with cvds, and the pooled prevalence was 35% (95% confidence interval [95% ci]: 28-42%). |
2023-04-01 |
2023-08-14 |
human |
| Xinrong Zuo, Xuehong Li, Kuo Tang, Rui Zhao, Minming Wu, Yang Wang, Tao L. Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis. Journal of cachexia, sarcopenia and muscle. 2023-04-01. PMID:37002802. |
the pooled prevalence of sarcopenia was 32% (95% ci: 23-41%) in patients with chronic heart failure (chf), 61% (95% ci: 49-72%) in patients with acute decompensated heart failure (adhf), 43% (95% ci: 2-85%) in patients with coronary artery disease, 30% (95% ci: 25-35%) in patients with cardiac arrhythmia (ca), 35% (95% ci: 10-59%) in patients with congenital heart disease and 12% (95% ci: 7-17%) in patients with unclassed cvds. |
2023-04-01 |
2023-08-14 |
human |
| Xinrong Zuo, Xuehong Li, Kuo Tang, Rui Zhao, Minming Wu, Yang Wang, Tao L. Sarcopenia and cardiovascular diseases: A systematic review and meta-analysis. Journal of cachexia, sarcopenia and muscle. 2023-04-01. PMID:37002802. |
however, in the general population, the prevalence of sarcopenia varied from 2.9% to 28.6% and the pooled prevalence was 13% (95% ci: 9-17%), suggesting that the prevalence of sarcopenia in patients with cvds was about twice compared with the general population. |
2023-04-01 |
2023-08-14 |
human |
| Molly Curtis, Lauren Swan, Rebecca Fox, Austin Warters, Maria O'Sulliva. Associations between Body Mass Index and Probable Sarcopenia in Community-Dwelling Older Adults. Nutrients. vol 15. issue 6. 2023-03-29. PMID:36986233. |
(3) results: our overall findings show that an underweight bmi was significantly associated with an increased likelihood of probable sarcopenia [or (ci) 2.25 (1.17, 4.33), |
2023-03-29 |
2023-08-14 |
Not clear |
| Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Natee Ina, Ply Chichareo. Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study. Scientific reports. vol 13. issue 1. 2023-03-09. PMID:36894658. |
the rate of tace response in patients with sarcopenia was not different from those without sarcopenia (60.91% vs. 65.22%, adjusted or 0.79, 95% ci 0.55-1.13). |
2023-03-09 |
2023-08-14 |
Not clear |
| Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Natee Ina, Ply Chichareo. Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study. Scientific reports. vol 13. issue 1. 2023-03-09. PMID:36894658. |
in the multivariable cox regression analysis, patients with myosteatosis or sarcopenia had higher risk of all-cause mortality than their counterparts (adjusted hazard ratio [hr] for myosteatosis versus no myosteatosis 1.66, 95% ci 1.37-2.01, adjusted hr for sarcopenia versus no sarcopenia 1.26, 95% ci 1.04-1.52). |
2023-03-09 |
2023-08-14 |
Not clear |
| Yu-Hsiang Tsai, Wan-Ming Chen, Ming-Chih Chen, Ben-Chang Shia, Szu-Yuan Wu, Chun-Chi Huan. Effect of Pre-Existing Sarcopenia on Oncological Outcomes for Oral Cavity Squamous Cell Carcinoma Undergoing Curative Surgery: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. Cancers. vol 14. issue 13. 2023-03-08. PMID:35805020. |
in multivariate cox regression analyses, the adjusted hazard ratio (ahr, 95% confidence interval [ci]) of all-cause mortality for ocscc with and without pre-existing sarcopenia was 1.15 (1.11−1.21, p < 0.0001). |
2023-03-08 |
2023-08-16 |
Not clear |
| Jui-An Lin, Jin-De Hou, Szu-Yuan W. Effect of Sarcopenia on Mortality in Type 2 Diabetes: A Long-Term Follow-Up Propensity Score-Matched Diabetes Cohort Study. Journal of clinical medicine. vol 11. issue 15. 2023-03-08. PMID:35956041. |
according to both univariate and multivariate cox regression analyses, the adjusted hazard ratios (ahrs; 95% confidence interval [ci]) of all-cause death for the sarcopenia diabetes group compared with the control group: 1.35 (1.33−1.38; p < 0.001). |
2023-03-08 |
2023-08-16 |
Not clear |
| Dara Aldisi, Mahmoud M A Abulmeaty, Tafany A Alsaawi, Abeer S Alorf, Gadah Mujlli, Atheer M Alshahrani, Rajwa M Alahmari, Mohammed Alquraishi, Nasser M Al-Daghri, Nawaf W Alruwaili, Shaun Sabic. Diagnostic Value of Inflammatory Markers in Elderly Arab Women with Sarcopenia. Diagnostics (Basel, Switzerland). vol 12. issue 10. 2023-03-08. PMID:36291982. |
lastly, participants with a tnf-α > 71.2 were five times more likely to have sarcopenia [(or = 5.85), 95% ci: 1.07−32.08; p = 0.04]. |
2023-03-08 |
2023-08-16 |
human |
| Erik Haehl, Luisa Alvino, Alexander Rühle, Jiadai Zou, Alexander Fabian, Anca-Ligia Grosu, Nils H Nicola. Sarcopenia as a Prognostic Marker in Elderly Head and Neck Squamous Cell Carcinoma Patients Undergoing (Chemo-)Radiation. Cancers. vol 14. issue 22. 2023-03-08. PMID:36428629. |
os was significantly deteriorated in sarcopenic patients with a median of 23 vs. 91 months (logrank p = 0.002) (hr 1.79, ci 1.22−2.60, p = 0.003) and sarcopenia remained an independent prognostic factor for reduced os in the multivariate analysis (hr 1.64, ci 1.07−2.52, p = 0.023). |
2023-03-08 |
2023-08-16 |
Not clear |
| Goh Eun Chung, Sohee Oh, Dong-Won Ahn, Su Hwan Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Ji Bong Jeon. Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease. Scientific reports. vol 13. issue 1. 2023-03-03. PMID:36869158. |
the or of interaction between obesity and sarcopenia affecting nafld was 8.46 (95% ci: 7.01-10.21). |
2023-03-03 |
2023-08-14 |
human |
| Goh Eun Chung, Sohee Oh, Dong-Won Ahn, Su Hwan Kim, Yong Jin Jung, Ji Won Kim, Byeong Gwan Kim, Kook Lae Lee, Ji Bong Jeon. Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease. Scientific reports. vol 13. issue 1. 2023-03-03. PMID:36869158. |
the or of interaction between sarcopenia and visceral adiposity affecting nafld was 7.25 (95% ci: 6.04-8.71), however, there was no significant additive interaction with reri = 0.87 (95% ci: -0.76 to 2.51). |
2023-03-03 |
2023-08-14 |
human |
| Francesco Pegreffi, Alice Balestra, Orazio De Lucia, Lee Smith, Mario Barbagallo, Nicola Verones. Prevalence of Sarcopenia in Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Journal of clinical medicine. vol 12. issue 4. 2023-02-25. PMID:36836065. |
pooling the data of the studies included that the prevalence of sarcopenia in knee oa was more than two times higher than in the control group (or = 2.07; 95%ci: 1.43-3.00; i |
2023-02-25 |
2023-08-14 |
human |
| Konstantinos Prokopidis, Panagiotis Giannos, Jean Yves Reginster, Olivier Bruyere, Mirko Petrovic, Antonio Cherubini, Konstantinos K Triantafyllidis, Konstantinos S Kechagias, Yannis Dionyssiotis, Matteo Cesari, Kinda Ibrahim, David Scott, Mario Barbagallo, Nicola Verones. Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis. Journal of cachexia, sarcopenia and muscle. 2023-02-13. PMID:36781175. |
sarcopenia was associated with a higher prevalence of polypharmacy (odds ratio [or]: 1.65, 95% confidence interval [ci] [1.23, 2.20], i |
2023-02-13 |
2023-08-14 |
Not clear |